Ignite Creation Date:
2025-12-24 @ 10:14 PM
Ignite Modification Date:
2025-12-25 @ 7:48 PM
Study NCT ID:
NCT05381935
Status:
WITHDRAWN
Last Update Posted:
2023-01-31
First Post:
2022-05-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Sponsor:
Elpiscience Biopharma, Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-04-21
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-04-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-04-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-11
First Submit QC Date:
None
Study First Post Date:
2022-05-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-01-30
Last Update Post Date:
2023-01-31
Last Update Post Date Type:
ACTUAL